Your browser doesn't support javascript.
loading
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Tesileanu, C Mircea S; Vallentgoed, Wies R; Sanson, Marc; Taal, Walter; Clement, Paul M; Wick, Wolfgang; Brandes, Alba Ariela; Baurain, Jean Francais; Chinot, Olivier L; Wheeler, Helen; Gill, Sanjeev; Griffin, Matthew; Rogers, Leland; Rudà, Roberta; Weller, Michael; McBain, Catherine; Reijneveld, Jaap; Enting, Roelien H; Caparrotti, Francesca; Lesimple, Thierry; Clenton, Susan; Gijtenbeek, Anja; Lim, Elizabeth; de Vos, Filip; Mulholland, Paul J; Taphoorn, Martin J B; de Heer, Iris; Hoogstrate, Youri; de Wit, Maurice; Boggiani, Lorenzo; Venneker, Sanne; Oosting, Jan; Bovée, Judith V M G; Erridge, Sara; Vogelbaum, Michael A; Nowak, Anna K; Mason, Warren P; Kros, Johan M; Wesseling, Pieter; Aldape, Ken; Jenkins, Robert B; Dubbink, Hendrikus J; Baumert, Brigitta; Golfinopoulos, Vassilis; Gorlia, Thierry; van den Bent, Martin; French, Pim J.
Afiliação
  • Tesileanu CMS; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • Vallentgoed WR; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • Sanson M; Sorbonne Universités UPMC University of Paris 06, Inserm, CNRS, APHP, Institut du Cerveau et de la Moelle (ICM)-Hôpital Pitié-Salpêtrière, Boulevard de l'hôpital, 75013, Paris, France.
  • Taal W; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • Clement PM; Department of Oncology, KU Leuven, Leuven, Belgium.
  • Wick W; Department of General Medical Oncology, UZ Leuven, Leuven, Belgium.
  • Brandes AA; Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik, Heidelberg, Germany.
  • Baurain JF; Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.
  • Chinot OL; Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium.
  • Wheeler H; Neuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.
  • Gill S; Northern Sydney Cancer Centre, St Leonards, NSW, 2065, Australia.
  • Griffin M; Department Medical Oncology, Alfred Hospital, Melbourne, Australia.
  • Rogers L; Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Rudà R; Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Weller M; Department of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.
  • McBain C; Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Reijneveld J; Department of Clinical Oncology, The Christie NHS FT, Manchester, UK.
  • Enting RH; Brain Tumor Center Amsterdam and Department of Neurology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Caparrotti F; Department of Neurology, UMCG, University of Groningen, Groningen, The Netherlands.
  • Lesimple T; Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.
  • Clenton S; Department of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.
  • Gijtenbeek A; Weston Park Hospital, Sheffield, UK.
  • Lim E; Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • de Vos F; Department of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.
  • Mulholland PJ; Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.
  • Taphoorn MJB; University College Hospital, London, UK.
  • de Heer I; MC Haaglanden, Den Haag, The Netherlands.
  • Hoogstrate Y; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • de Wit M; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • Boggiani L; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • Venneker S; Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  • Oosting J; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Bovée JVMG; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Erridge S; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Vogelbaum MA; Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburg, UK.
  • Nowak AK; Department of NeuroOncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Mason WP; School of Medicine and Pharmacology, University of Western Australia, 35 Stirling, Highway Crawley, WA, 6009, Australia.
  • Kros JM; CoOperative Group for NeuroOncology, University of Sydney, Camperdown, NSW, Australia.
  • Wesseling P; Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, 6009, Australia.
  • Aldape K; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Jenkins RB; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Dubbink HJ; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
  • Baumert B; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Golfinopoulos V; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Gorlia T; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • van den Bent M; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Center (MUMC) and GROW (School for Oncology), Maastricht, The Netherlands.
  • French PJ; Institute of Radiation-Onology, Chur, Switzerland.
Acta Neuropathol ; 141(6): 945-957, 2021 06.
Article em En | MEDLINE | ID: mdl-33740099
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Astrocitoma / Neoplasias Encefálicas / Metilação de DNA / Isocitrato Desidrogenase / Mutação Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Astrocitoma / Neoplasias Encefálicas / Metilação de DNA / Isocitrato Desidrogenase / Mutação Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda